MGI Tech Co. Ltd. (“MGI”), a company committed to building the essential tools and technology to lead the life sciences, today is proud to announce the DNBSEQ-T20×2 (“T20”) The genetic sequencing platform has been awarded the BEYOND Healthcare Innovation Award.
We are honored to receive this prestigious award. The T20 is a testament to our commitment to providing innovative solutions that enable scientists to advance research and improve healthcare outcomes. We are proud to be at the forefront of the genomics revolution and look forward to continuing to innovate and push the boundaries of what is possible in this field.”
Duncan Yu, President, MGI.
The BEYOND Healthcare Award was launched by BEYOND Expo in 2020 to honor healthcare companies that deliver innovative products and services with cutting-edge technologies and industry-leading solutions and to highlight the potential for technological innovation. At the 2023 Awards Ceremony held on May 12, MGI won the award for the T20, a genome sequencer that broke records for superior throughput and cost efficiency with the ability to produce up to 50,000 whole-genome sequences per year per branch. One hundred dollars per genome.
T20 was first presented at Advances in Genome Biology and Technology (AGBT) in the United States in February 2023. Its launch has accelerated understanding of the human genome and medical applications, advancing global genomics and fundamentally reshaping the industrial ecosystem. Since then, T20 has been widely adopted by research institutions and healthcare providers. In April 2023, MGI obtained its first T20 company order with JMDNA Biomedical Technology Co., Ltd. Based in Shanghai. The ability to widely provide affordable, high-quality sequence data has made it an attractive tool for researchers and clinicians looking to expand their genomic research capabilities to advance their research.
Gene Sequencer is the supreme product that integrates frontier knowledge in science with the latest technology and components from various fields, including mechanics, engineering, electronics, automation, acoustics, optics, mathematics, chemistry, biology, and computer science. At the same time, as an essential tool in life sciences, it has proven great value in research, clinical diagnosis, disease treatment and other fields for its highly precise functions.
MGI is one of two companies in the world that can develop and mass-produce clinical gene sequences of low, medium and high throughput from Gb to Tb. Equipped with the ability to provide diverse genetic sequencers covering a wide range of low, medium to very high throughput sequencing applications, MGI offers a one-stop shop for customers based on their diverse genomic needs.